Effect of stiripentol dose on phenytoin-induced teratogenesis in a mouse model

Reproductive Toxicology

Volumn 13, Issue 2, 1999, Pages 85-91

  Finnell, Richard H ^a   Bennett, Gregory D ^a   Mather, Gary G ^b   Wlodarczyk, Bogdan ^a   Bajpai, Manoj ^b   Levy, René H ^b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Birth defects; Epilepsy; Phenytoin; Pregnancy; Stiripentol; Teratogen

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ANTICONVULSIVE AGENT; CARBON; CARBON 14; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PHENYTOIN; PIPERONYL BUTOXIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; STIRIPENTOL;

ANIMAL; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTICONVULSANT THERAPY; ARTICLE; BIRTH DEFECT; BLOOD; CONGENITAL MALFORMATION; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; EMBRYO; EPILEPSY; FEMALE; FETUS MALFORMATION; MOUSE; MOUSE STRAIN; NONHUMAN; ORAL DRUG ADMINISTRATION; PREGNANCY; PREGNANCY COMPLICATION; TERATOGENESIS;

EID: 0033103412     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0890-6238(98)00067-7     Document Type: Article

References (31)

1. Finnell R.H., Dansky L.V. Parental epilepsy, anticonvulsant drugs, and reproductive outcome epidemiologic and experimental findings spanning three decades. I. Animal studies . Reprod Toxicol. 5:1991;281-299.
2. Finnell R.H., Nau H., Yerby M.S. General principles teratogenicity of antiepileptic drugs . Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic drugs. 4th ed. 1995;209-230 Raven Press, New York.
3. Martz F., Fallinger C., Blake D.A. Phenytoin teratogenesis correlation between embryopathic effect and covalent binding of putative arene oxide metabolite in gestational tissue . J Pharmacol Exp Ther. 203:1977;231-239.
4. Blake D.A., Martz F. Covalent binding of phenytoin metabolites in fetal tissue. Hassell T.M., Johnston M.C., Dudley K.H. Phenytoin-induced teratology and gingival pathology. 1980;75-82 Raven Press, New York.
5. Wells P.G., Harbison R.D. Significance of the phenytoin reactive arene oxide intermediate, its oxepin tautomer, and clinical factors modifying their roles in phenytoin-induced teratology. Hassell T.M., Johnston M.C., Dudley K.H. Phenytoin-induced teratology and gingival pathology. 1980;83-112 Raven Press, New York.
6. Finnell R.H., Buehler B.A., Kerr B.M., Ager P.L., Levy R.H. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology. 42:(Suppl 5):1992;25-31.
7. Levy R.H., Loiseau P., Guyot M., Blehaut H.M., Tor J., Moreland T. Stiripentol kinetics in epilepsy nonlinearity and interactions . Clin Pharmacol Ther. 36:1984;661-669.
8. Levy R.H., Loiseau P., Guyot M., Acheampong A., Tor J., Rettenmeier A.W. Effects of stiripentol on valproate plasma level and metabolism. Epilepsia. 28:1987;605.
9. Rush W.R., Smith S.A., Mulvey J.H., Graham D.J., Chaplin M.D. Inhibition and induction of hepatic drug metabolism in rats and mice by nafimidone and its major metabolite nafimidone alcohol. Drug Metab Dispos. 15:1987;571-578.
10. Finnell R.H., van Waes M., Musselman A., Kerr B.M., Levy R.H. Differences in the patterns of phenytoin-induced malformations following stiripentol coadministration in three inbred mouse strains. Reprod Toxicol. 7:1993;439-448.
11. Finnell R.H., Kerr B.M., van Waes M., Steward R.L., Levy R.H. Protection from phenytoin-induced congenital malformations by coadministration of the antiepileptic drug stiripentol in a mouse model. Epilepsia. 35:1994;141-148.
12. Crary D.D. Modified benzyl alcohol clearing of alizarin-stained specimens without loss of flexibility. Stain Technol. 37:1962;124-125.
13. Barrow M.W., Taylor J.P. A rapid method for detecting malformations in rat fetuses. J Morphol. 127:1969;291-306.
14. Kushida K., Chiba K., Ishizaki T. Simultaneous liquid chromatographic determination of chloramphenicol and antiepileptic drugs (phenobarbital, phenytoin, carbamazepine, and primidone) in plasma. Ther Drug Monit. 5:1983;127-133.
15. Lin H., Levy R.H. Pharmacokinetic profile of a new anticonvulsant, stiripentol, in the rhesus monkey. Epilepsia. 24:1983;692-702.
16. Thummel K.E., Kharasch E.D., Podoll T., Kunze K. Human liver microsomal enflurane defluorination catalysed by P-450 2E1. Drug Metab Dispos. 21:1993;350-357.
17. Sokal R.R., Rohlf F.J. Biometry. The principles and practice of statistics in biological research. 1981;W.H. Freeman, San Francisco.
18. Finnell R.H. Phenytoin-induced teratogenesis a mouse model . Science. 211:1981;483-484.
19. Finnell R.H., Abbott L.C., Taylor S.M. The fetal hydantoin syndrome answers from a mouse model . Reprod Toxicol. 3:1989;127-133.
20. Gerber N., Arnold K. Studies on the metabolism of diphenylhydantoin in mice. J Pharmacol Exp Ther. 167:1969;77-90.
21. Roy D., Snodgrass W.R. Phenytoin metabolic activation role of cytochrome P450, glutathione, age, and sex in rats and mice . Res Commun Chem Pathol Pharmacol. 59:1988;173-190.
22. Gibson J.E., Becker B.A. Teratogenic effects of diphenylhydantoin in Swiss-Webster and A/J mice. Proc Soc Exp Biol Med. 128:1968;905-909.
23. Harbison R.D., Becker B.A. Relation of dosage and time of administration of diphenylhydantoin. Teratology. 2:1969;305-312.
24. Rutledge J.C., Generoso W.M., Shourbaji A., Cain K.T., Gans M., Oliva J. Developmental anomalies derived from exposure of zygotes and first-cleavage embryos to mutagens. Mutat Res. 296:1992;167-177.
25. Jerina D.M., Daly J.W. Arene oxides a new aspect of drug metabolism . Science. 185:1974;573-582.
26. Wells P.G., Vo H.P.N. Effects of the tumor promoter 12-O-tetradecanolylphorbol-13-acetate on phenytoin-induced embryopathy in mice. Toxicol Appl Pharmacol. 97:1989;398-405.
27. Strickler S.M., Dansky L.V., Miller M.A., Seni M.H., Andermann E., Spielberg S.P. Genetic predisposition to phenytoin-induced birth defects. Lancet. 2:1985;746-749.
28. Kerr B.M., Martínez-Lage J.M., Viteri C., Tor J., Eddy A.C., Levy R.H. Carbamazepine dose requirements during stiripentol therapy influence of cytochrome P-450 inhibition by stiripentol . Epilepsia. 32:1991;267-274.
29. Mesnil M., Testa B., Jenner P. In vitro inhibition by stiripentol of rat brain cytochrome p450-mediated napthalene hydroxylation. Xenobiotica. 18:1988;1097-1106.
30. Loiseau P., Duché B. Stiripentol. Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic drugs, 4th ed. 1995;1045-1056 Raven Press, New York.
31. Tran A., Rey E., Pons G., et al. Influence of stiripentol on P450-mediated metabolic pathways in humans in vitro and in vivo comparison and calculation of in vivo inhibition constants . Clin Pharmacol and Ther. 62:1997;490-504.